Max Robotics — Global Service Robot Directory + US Certification

About

Kanetaka Miyazaki is a pioneering urologic surgeon whose work is reshaping the landscape of prostate and bladder cancer treatment. His primary research focuses on refining robot-assisted radical prostatectomy (RARP) techniques to maximize both oncological control and post-surgical quality of life. Miyazaki’s most impactful contribution is the development of a novel nerve-sparing RARP approach that preserves the endopelvic fascia, a technique designed to significantly reduce post-operative incontinence. His landmark 2024 study, which has garnered 11 citations, provides the first long-term evidence that this method achieves excellent functional outcomes without compromising cancer control, offering a new gold standard for surgical precision. Beyond prostate cancer, Miyazaki has made notable strides in precision oncology, as demonstrated by his 2022 case report on a patient with the aggressive plasmacytoid variant of bladder cancer. By using genomic analysis to guide treatment, he achieved a pathological complete response with pembrolizumab, showcasing the power of personalized medicine. Additionally, he developed and validated a novel nomogram for extended pelvic lymph node dissection in the robotic era, a tool that helps surgeons identify high-risk prostate cancer patients, thereby minimizing unnecessary procedures. With a growing body of work that seamlessly integrates surgical innovation, predictive modeling, and molecular insights, Miyazaki is a leading voice in the future of urologic oncology.